Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARG | Q86W56 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.37 |
| ▸ | KDM2B | Q8NHM5 | 4/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL627531 | 0.84 | GRM2 (0.41) | PARGGRM2KDM2BMETAP2 | |
| SCHEMBL626500 | 0.84 | MAPK14 (0.52) | PARGCYP1A2GRM2MAPK14OPRM1 | |
| SCHEMBL625470 | 0.82 | BRD4 (0.47) | GRM2OPRM1ADORA2AALDH1A1 | |
| SCHEMBL627103 | 0.81 | GRM2 (0.47) | PARGGRM2MAPK14OPRM1ADORA2A | |
| SCHEMBL10146576 | 0.80 | GRM2 (0.64) | PARGGRM2MAPK14 | |
| SCHEMBL14992331 | 0.79 | GRM2 (0.40) | PARGGRM2KDM2BOPRM1METAP2 | |
| SCHEMBL10145991 | 0.79 | PARG (0.57) | PARGGRM2ADORA2AADORA2BMETAP2 | |
| SCHEMBL10146337 | 0.75 | GRM2 (0.43) | PARGGRM2OPRM1METAP2 | |
| SCHEMBL625527 | 0.70 | GRM2 (0.51) | PARGGRM2KDM2B | |
| SCHEMBL14992698 | 0.70 | PARG (0.45) | PARGCYP1A2GRM2OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993779-B2 | Positive allosteric modulators of MGLUR2 | MERCK SHARP & DOHME CORP. (US) | 2015-03-31 | — | — | US | claimed |
| EP-2603079-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | Merck Sharp & Dohme Corp. (US) | 2013-06-19 | — | — | EP | claimed |
| US-20130143880-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME LLC | 2013-06-06 | — | — | US | claimed |
| WO-2012021382-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME CORP. (US) | 2012-02-16 | — | — | WO | claimed |
| US-8993779-B2 | Positive allosteric modulators of MGLUR2 | MERCK SHARP & DOHME CORP. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993779-B2 | Positive allosteric modulators of MGLUR2 | MERCK SHARP & DOHME CORP. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20130143880-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME LLC | 2013-06-06 | — | — | US | disclosed |
| US-20130143880-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME LLC | 2013-06-06 | — | — | US | disclosed |
| WO-2012021382-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME CORP. (US) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143880-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | GRM2, GRIA2, GRM1 | PARG 4723/4885CYP1A2 3682/4885GRM2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.